

ASX/Media Release

27 July 2018

Botanix expands clinical capabilities

Key highlights

- Botanix has expanded its clinical capabilities with the appointment of a Chief Medical Officer and Senior Director of Clinical Operations
- Dr Stephane Levy and Ms Jillian Chapas-Reed join the Company to help accelerate the BTX 1503 acne and BTX 1204 atopic dermatitis Phase 2 clinical trials
- Appointments bring significant clinical expertise in acne, dermatitis and psoriasis and extensive late stage clinical development experience to Botanix
- Botanix is fully funded to complete two Phase 2 clinical trials in multi-billion dollar markets and is progressing other exciting dermatology pipeline products

Philadelphia PA and Sydney Australia, 27 July 2018: Medical dermatology company Botanix Pharmaceuticals (“Botanix” or “the Company”) today announced the appointment of two highly qualified global pharmaceutical industry executives to expand the Company’s clinical development capabilities. The Company appointed Dr Stephane Levy as Chief Medical Officer and Ms Jillian Chapas-Reed as Senior Director of Clinical Operations.

Matt Callahan, Founder and Executive Director of Botanix said: “We are very pleased to welcome both Stephane and Jillian to the team. Both of them bring highly relevant experience and technical knowledge to Botanix, which will help accelerate development of our lead Phase 2 clinical programs in acne and atopic dermatitis, as well as our growing pipeline of dermatology products.”

Dr Levy brings significant experience having most recently been the Vice-President of Research and Development at global dermatology company Almirall’s US subsidiary Aqua Pharmaceuticals. Prior to that, Dr Levy was Vice President and Medical Unit Head of Immunology and Dermatology for Novartis in the US, and Vice President North America Medical Affairs for Sanofi. As part of these roles, Dr Levy has been responsible for clinical development and clinical medical affairs programs, which led to recent successful launches of prescription and cosmetic dermatology products.

Dr Levy said: “I am excited about joining the Company at this important time, as Botanix’s acne and atopic dermatitis programs progress into Phase 2 clinical trials. It is clear that patients and their health care providers still need new therapies to treat these skin diseases. The data already generated by Botanix with their unique products, provides great potential for success.”

Ms Chapas-Reed also brings significant experience in both clinical trial management and dermatology and joins Botanix from Churchill Pharmaceuticals (Churchill) where she most recently led a Phase 2/3 study that was successfully approved by the FDA in May 2018. Prior to Churchill, Ms Chapas-Reed

worked with both pharmaceutical development and clinical trial services companies managing several clinical trials ranging from atopic dermatitis to pain.

The appointment of Dr Levy and Ms Chapas-Reed follows Botanix's recent recruitment of first patients into the BTX 1503 acne Phase 2 clinical trial and comes as the Company is actively preparing to commence its second Phase 2 clinical trial for BTX 1204 (treatment of atopic dermatitis). Both products have been rapidly progressed from early stage formulation development to successful clinical studies in patients within the last 24 months. The combination of BTX 1503, BTX 1204 and pipeline products in psoriasis (BTX 1308) and antimicrobials (BTX 1801), represent a diverse and valuable portfolio of dermatology products.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage medical dermatology company based in Perth, Australia and Philadelphia, PA. The Company's focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of a widely studied natural compound. Treatment targets include inflammation, deterioration of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.

Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of Permetrex™ on both a fee-for-service and traditional license basis.

Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation. The patient treatment duration of clinical studies is generally completed within a 4 to 12 week timeframe.

The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical trial in June 2018 with completion expected in mid-2019. The Phase 1b BTX 1204 atopic dermatitis patient study concluded in June 2018 and preparation is underway for a Phase 2 clinical trial. A further Phase 1b BTX 1308 psoriasis patient study is also scheduled to commence in 3Q CY2018.

For more information on Botanix, please visit www.botanixpharma.com

For more information, please contact:

General enquiries

Matt Callahan
Botanix Pharmaceuticals
Founder & Executive Director
+1 215 767 4184

mcallahan@botanixpharma.com

Investor enquiries

Joel Seah
Vesparum Capital

P: +61 3 8582 4800

botanixpharma@vesparum.com

Media enquiries

Julia Maguire
The Capital Network

P: +61 419 815 386

julia@thecapitalnetwork.com.au